Finding a cure through funding vital research
There are currently very few treatments showing any efficacy (scientifically documented and proven) and no cure available for DIPG
Research initiatives and funding of this work enabling doctors to get a better understanding of how DIPG develops and progresses, is the only way to lead development of effective treatment options, and techniques to benefit ALL children affected by DIPG.
Here are some of the latest developments :
Potent antitumor efficacy of Anti-GD2 CAR-T cells in H3 K27M +diffuse midline gliomas
Histone H3.3K27M Mobilizes Multiple Cancer/Testis (CT) Antigens in Pediatric Glioma
Study splits incurable childhood brain tumours into 10 new diseases
Targeting a protein called neuroligin-3
Influence of an intratumoral cyst on drug distribution by convection-enhanced delivery: case report
Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management
Restoring the tumor suppressor gene p16 slows tumor growth in vitro
EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.
Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas
Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors
BMI-1 is a Potential Therapeutic Target in Diffuse Intrinsic Pontine Glioma
A phase I study of convection enhanced delivery (CED) of 124I-8H9 radio-labeled monoclonal antibody in children with diffuse intrinsic pontine glioma (DIPG).
External validation of the diffuse intrinsic pontine glioma survival prediction model: a collaborative report from the International DIPG Registry and the SIOPE DIPG Registry.
Repurposing the anti-epileptic drug sodium valproate as an adjuvant treatment for diffuse intrinsic pontine glioma
Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models